Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8962572 | FRESENIUS KABI USA | Bortezomib formulations |
Nov, 2032
(9 years from now) |
Market Authorisation Date: 06 November, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6958319 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(1 year, 2 days ago) | |
US6713446 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(1 year, 2 days ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6713446
(Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(6 months ago) | |
US6958319
(Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(6 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Pediatric Exclusivity (PED) | Apr 8, 2022 |
Market Authorisation Date: 13 May, 2003
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic